Company intelligence / Profile preview

中曦

Beijing, Beijing, China

Ownership: Private
Development stage: Other

Overview

Zhongxi Biotech is a Chinese biotechnology company specializing in the development of mRNA-based therapeutics and vaccines. Founded in 2021 and headquartered in Beijing, the company focuses on leveraging its proprietary mRNA synthesis and lipid nanoparticle (LNP) delivery platforms to address unmet needs in infectious diseases and oncology. Its research and development efforts are centered on optimizing mRNA stability and delivery efficiency to create next-generation prophylactic and therapeutic solutions. Zhongxi Biotech is currently advancing several candidates through pre-clinical development, including vaccines for viral infections and personalized cancer immunotherapies.

Therapeutic areas: Infectious DiseasesOncology
Modalities: mRNA-based drugsLipid nanoparticle delivery therapyBiologic
Industry: Biotech

Beyond the preview

Go deeper on 中曦.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 中曦.

Explore the full profile